BETA

IPO registrations (S-1, F-1) · Registrants

Baxalta Inc

SEC CIK
1620546 · filings on EDGAR ↗
Registration
Form S-1, first filed 2015-06-23, last 2016-03-15; 3 initial registrations, 6 amendments
Outcome
Final prospectus filed 2016-01-28; declared effective 2015-07-09
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
DE
Business address
1200 LAKESIDE DRIVE, Bannockburn, IL 60015
EIN
47-1869689
EDGAR entity type
operating
Insiders and CEO pay
Baxalta Inc on the corporate pages

Offering terms

Final price
$39.50 per ADS (424B4 filed 2016-01-28)
Shares sold
37,573,040
Gross proceeds
$1,484,135,080 before underwriting discounts and any over-allotment option
Listing
NYSE under the symbol BXLT
Lead underwriters
J.P. Morgan (37,573,040 shares)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 17

FiledFormWhat it isName as filedEDGAR
2015-06-23S-1S-1 (registration)Baxalta Inc0001193125-15-232029 ↗
2015-07-07S-1/AS-1/A (amendment)Baxalta Inc0001193125-15-246877 ↗
2015-07-09EFFECTEFFECT (declared effective)Baxalta Inc9999999995-15-001874 ↗
2015-09-01S-1S-1 (registration)Baxalta Inc0001193125-15-309472 ↗
2016-01-15S-1/AS-1/A (amendment)Baxalta Inc0001193125-16-431188 ↗
2016-01-26S-1/AS-1/A (amendment)Baxalta Inc0001193125-16-437135 ↗
2016-01-26S-1/AS-1/A (amendment)Baxalta Inc0001193125-16-438507 ↗
2016-01-27EFFECTEFFECT (declared effective)Baxalta Inc9999999995-16-003601 ↗
2016-01-28424B4424B4 (final prospectus)Baxalta Inc0001193125-16-442124 ↗
2016-02-03S-1S-1 (registration)Baxalta Inc0001193125-16-449415 ↗
2016-03-10EFFECTEFFECT (declared effective)Baxalta Inc9999999995-16-003921 ↗
2016-03-11S-1/AS-1/A (amendment)Baxalta Inc0001193125-16-501682 ↗
2016-03-15S-1/AS-1/A (amendment)Baxalta Inc0001193125-16-505155 ↗
2016-03-16EFFECTEFFECT (declared effective)Baxalta Inc9999999995-16-003967 ↗
2016-03-17424B4424B4 (final prospectus)Baxalta Inc0001193125-16-508601 ↗
2016-04-29EFFECTEFFECT (declared effective)Baxalta Inc9999999995-16-004455 ↗
2016-05-13EFFECTEFFECT (declared effective)Baxalta Inc9999999995-16-004663 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2016-01-26S-1/Aregistration statement$1.00131,902,719$131,902,719NYSE BXLT1primary document; price sentence, shares headline, proceeds computeddocument ↗
2016-01-28424B4final prospectus$39.5037,573,040$1,484,135,080NYSE BXLT1primary document; price to public, shares headline, proceeds table, underwriting table 1document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
BAXTER INTERNATIONAL INCTenPercentOwner42015–2016
HANTSON LUDWIGDirector,OfficerChairman of the Board and CEO; President and CEO62015–2016
HOCKMEYER WAYNE TDirector42015–2016
HOMBACH ROBERT J.Director,Officer; OfficerCVP and CFO; EVP, CFO and COO; EVP. CFO and COO62015–2016
Scharf David P.Director,OfficerSee Remarks12015
Devitt Blake EDirector62015–2016
Edwards Peter GOfficerEVP and General Counsel; SVP and General Counsel; SVP AND GENERAL COUNSEL42015–2016
FORSYTH JOHN DDirector52015–2016
FOSLER GAIL DDirector42015–2016
GAVIN JAMES R IIIDirector62015–2016
GLASSPOOL JOHNOfficerSee Remarks82015–2016
Goff BrianOfficerEVP and President, Hematology; See Remarks72015–2016
LAW ANNE-MARIEOfficerEVP & Head of Human Resources; See Remarks52015–2016person page Fuzzy
LEONARDI JACOPOOfficerEVP and President, Immunology82015–2016
MCCOY JOHN A.OfficerSee Remarks; SVP and Controller82015–2016
Meek David D.OfficerEVP and President, Oncology; See Remarks52015–2016
ORLOFF JOHN JOfficerEVP and President, R&D; See Remarks42015–2016
ROSA-BJORKESON DAGMAROfficerEVP and President, Biosimilars; See Remarks62015–2016
STROUCKEN ALBERT P LDirector52015–2016person page Fuzzy
ZAGAME PATRICEOfficerSee Remarks42015–2016
Ferrante Karen JeanDirector42015–2016
Nader FrancoisDirector42015–2016

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationBAXALTA INCORPORATEDILState business registriesEIN (EXACT, as the state registration reports it)
SEC filerBaxalta IncSEC filers (EDGAR)CIK (EXACT)
Business registrationBAXALTA IncorporatedState business registriesname and state
Form 5500 plan sponsorBAXALTA INCORPORATEDEIN (EXACT)
Lobbying clientBAXALTAFederal lobbying (LDA)name and state
Lobbying clientBAXALTAFederal lobbying (LDA)name and state
Person pageAlbert P L StrouckenPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director)
Person pageAnne-Marie LawPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Pharmaceutical Preparations, IL first:

More with this interest.

In other datasets, the same topic (Health) in IL:

Interests: Pharmaceutical Preparations · Health